Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction With and Without Atherosclerosis

This large pooled analysis of nearly 430,000 individuals delivered one of the clearest statements yet in the particle-number debate: when apolipoprotein B and LDL cholesterol disagree, risk tracks with apoB.

In primary prevention, each standard deviation increase in apoB was associated with a 38 percent higher MI risk — an association that persisted after adjusting for non-HDL cholesterol. When the analysis was restricted to discordant cases (high apoB, low LDL-C), risk followed the apoB signal. Neither non-HDL-C nor LDL-C added independent risk prediction once apoB was accounted for. Conversely, adjusting apoB for LDL-C produced no attenuation — confirming that cholesterol concentration is a downstream attribute of what apoB directly measures: atherogenic particle number.

The clinical message is unambiguous. ApoB is not a refinement of LDL cholesterol; it is the more fundamental measurement. Every LDL particle carries one apoB molecule. Counting apoB molecules counts particles. Measuring LDL cholesterol instead measures the average lipid filling per particle — which varies. When particles are small and dense (as in metabolic syndrome, diabetes, hypertriglyceridemia), LDL-C systematically underestimates particle number and therefore risk.

We rate the evidence strong, with high clinical significance. A very large, contemporary cohort study delivering definitive confirmation that apoB — not LDL-C or non-HDL-C — is the primary driver of myocardial infarction risk.